Gangcheng Zhang

Gangcheng Zhang

Auto-generated profile, based on publicly available information

Gangcheng Zhang

Department of Cardiology, Wuhan Asia Heart Hospital, Wuhan, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Pulmonary Circulation
Verified
Journal Article
Open access
PDF file
HZHongmei Zhou
Hongmei Zhou
GZGangcheng Zhang
Gangcheng Zhang
XDXiaoxian Deng
Xiaoxian Deng
BJBowen Jin
Bowen Jin
QQQiu Qiu
Qiu Qiu
XZXuan Zheng
Xuan Zheng
Pulmonary hypertension is a chronic disease developing progressively with high mortality. Pulmonary hypertension patients need persistent medical care; however, limited reports focused on them when there was an outbreak of coronavirus disease 2019 in China. This national survey was aimed to evaluate the overall condition of pulmonary hypertension patients during this period. A questionnaire regarding the living condition of pulmonary hypertension patients during coronavirus disease 2019 was designed by pulmonary hypertension diagnostic experts in Wuhan Asia Heart Hospital. Pulmonary hypertension patients and their family members were invited to participate in this survey online. One‐hundred twenty pulmonary hypertension patients and 23 family members participated in the survey; 64.8% (n = 87) participants came from Hubei, and others were from 15 other provinces; 98.6% (n = 141) participants were in home quarantine; 65.8% (n = 79) were pulmonary arterial hypertension associated with congenital heart disease; and 76.7% (n = 92) patients proclaimed their heart function was well maintained at class I or II. One (0.8%) patient was confirmed severe acute respiratory syndrome coronavirus 2 infection. Two (1.7%) patients were hospitalized due to heart function worsening. Nearly 70% (n = 100) participants implied shortage in medications during coronavirus disease 2019 outbreak. A total of 24.2% (n = 29) patients indicated that medications were discontinued due to the insufficient supply. Most of the participants stayed optimistic on either coronavirus disease 2019 outbreak or their pulmonary hypertension disease, and 61.7% (n = 74) patients would go to the hospital for follow‐up immediately after outbreak. These preliminary data show pulmonary hypertension patients are able to avoid severe disease when they are in home quarantine. Medication supplement is important for pulmonary hypertension patients when their heart function is well maintained. In addition, there might be increasing requirements of medical care for pulmonary hypertension patients after the outbreak.

1 April 2023 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
FLFeng Li
Feng Li
QSQunshan Shen
Qunshan Shen
XDXiaoxian Deng
Xiaoxian Deng
MYMenghuan Yan
Menghuan Yan
XZXuan Zheng
Xuan Zheng
GZGangcheng Zhang
Gangcheng Zhang
Background: Agitated saline (AS) with blood has been shown to have good tolerance and increased efficacy when used in contrast-enhanced transcranial Doppler (c-TCD) to detect right-to-left shunt (RLS). However, little is known about the effects of blood volume on c-TCD results. Our study investigated the characterization of AS with different blood volumes in vitro and compared the c-TCD results in vivo. Methods: In vitro, AS without blood, AS with 5% blood (5% BAS), and AS with 10% blood (10% BAS) were prepared based on previous studies and observed under microscopy. The numbers and sizes of the microbubbles from different contrast agents were compared immediately, 5 min, and 10 min post-agitation. In vivo, 74 patients were recruited. c-TCD was repeated 3 times using AS with different blood volumes in each patient. Signal detection times, positive rates, and classifications of RLS were compared among the 3 groups. Results: In vitro, the AS without blood produced 5.4±2.4/field microbubbles after agitation, the 5% BAS produced 30.4±4.2/field, and the 10% BAS produced 43.9±12.7/field. More microbubbles remained in the 10% BAS than the 5% BAS within 10 min (18.5±6.1 vs. 7.1±2.0/field, P<0.001). The size of the microbubbles from the 5% BAS increased from 9.2±8.2 to 22.1±10.6 µm within 10 min post-agitation (P=0.014), while the 10% BAS changed insignificantly. In vivo, the signal detection times of the 5% BAS (1.1±0.7 s) and 10% BAS (1.0±0.8 s) were significantly shorter than the AS without blood (4.0±1.5 s, P<0.0001). The RLS positive rates were 63.5%, 67.6% and 71.6% in AS without blood, 5% BAS and 10% BAS respectively; however, the differences were not statistically significant. The AS without blood reached 12.2% level III RLS, while the 5% BAS reached 25.7%, and the 10% BAS reached 35.1% (P=0.005). Conclusions: The 10% BAS would be suggested in c-TCD as it addressed larger RLS by increasing the number and stability of microbubbles, and it improves the diagnosis of patent foramen ovale (PFO).

1 April 2025 in Pulmonary Circulation
Verified
Journal Article
Open access
HZHaojie Zhang
Haojie Zhang
MYMenghuan Yan
Menghuan Yan
FLFeng Li
Feng Li
QCQi Chen
Qi Chen
RLRui Lu
Rui Lu
GZGangcheng Zhang
Gangcheng Zhang
Pulmonary hypertension (PH) is a life‐threatening condition frequently associated with exertional dyspnea. It remains diagnostically challenging due to limitations in current screening modalities. While the 6‐min walk test (6MWT) has been applied for risk stratification in confirmed PH, its potential role in screening remains unexplored. This retrospective cohort study investigated the diagnostic utility of 6MWT‐derived parameters in 180 patients with exertional dyspnea. PH diagnosis was confirmed by right heart catheterization with the definition of mean pulmonary artery pressure > 20 mmHg. Among 79 PH patients (43.9%), a significantly reduced 6‐min walk distance (6MWD) was observed compared to non‐PH patients (469.5 ± 106.4 m vs. 509.8 ± 74.9 m, p = 0.019). Continuous physiological monitoring revealed that the SpO₂ trough and the heart rate (HR) peak occurred at different time points during 6MWT. Propensity score‐matched case‐control analysis further demonstrated greater exercise‐induced desaturation of SpO2 from the rest to minimal levels (ΔSpO₂rest−min: 9 ± 9% vs. 4 ± 6%, p < 0.001) and exaggerated HR response from the rest to maximal levels (ΔHRmax−rest: 51±21bpm vs. 34±14bpm, p < 0.001) in PH patients. Multivariable analysis identified ΔSpO₂rest−min ≥ 5% (AUC = 0.715, 95% CI: 0.640–0.852; p < 0.001) and ΔHRmax−rest ≥ 42 bpm (AUC = 0.740, 95% CI: 0.656–0.823; p < 0.001) as independent predictors of PH. The number of these predictors discriminated the risk of PH in dyspneic patients. A risk‐stratification model incorporating these thresholds demonstrated improved predictive value for PH screening, with a C‐statistic of 0.786 (95% CI: 0.710–0.863, p < 0.001). These findings suggest that parameters derived from the 6MWT, particularly exercise‐induced SpO₂ desaturation and HR response, may facilitate noninvasive PH screening in exertional dyspneic patients.

1 May 2023 in Journal of Thoracic Disease
Verified
Journal Article
Open access
JCJinsong Cao
Jinsong Cao
XZXuan Zheng
Xuan Zheng
MCMing Chen
Ming Chen
XLXintan Liu
Xintan Liu
JLJinping Liu
Jinping Liu
GZGangcheng Zhang
Gangcheng Zhang
Transcatheter aortic valve replacement (TAVR) is emerging as a less invasive procedure for aortic valve replacement. However, its effectiveness and feasibility in treating combined valvular disease remain controversial. In this study, we explored the clinical effectiveness and safety of TAVR in the treatment of combined aortic and mitral regurgitation. The basic clinical characteristics and 1-month follow-up of 11 patients with combined aortic and mitral regurgitation who were treated with TAVR at center of structural heart disease, Zhongnan Hospital of Wuhan University from December 2021 to November 2022 were retrospectively analyzed. Echocardiographic parameters of aortic and mitral valve, complications, and all-cause mortality were compared pre- and post-TAVR. Retrievable self-expanding valve protheses were used in all patients, and the protheses were implanted via the transfemoral route in 8 patients and via the transapical route in 3 patients. There were 9 male and 2 female patients with an average age of 74.7±2.7 years. The mean Society of Thoracic Surgeons score was 8.5±1.2. Among the patients, 1 required retroperitoneal sarcoma semi-elective surgery, and 3 of the 5 patients with atrial fibrillation had their rhythm converted to sinus rhythm after operation. No perioperative deaths were recorded. Two patients underwent permanent pacemaker implantations due to high-grade atrioventricular blocks after TAVR. Moderate/severe mitral regurgitation (MR) were mostly secondary to aortic regurgitation (AR) as no rupture of the subvalvular tendon cords or rheumatic changes being recognized during echocardiography before operation. The mean left ventricular end-diastolic diameter (65.5±10.7 vs. 58.6±8.8 mm, P<0.001) and mitral annular diameter (36.7±5.4 vs. 31.5±2.8 mm, P<0.001) was significantly reduced after operation. MR was improved as the ratio of the regurgitant jet area to the left atrial area decreased significantly after operation (24.7%±11.5% vs. 42.4%±6.8% before operation, P<0.001). During the 1-month follow-up, the mean left ventricular ejection fraction was significantly improved (50.0%±9.4% vs. 44.6%±9.3% at admission, P=0.022). TAVR is effective and feasible for high-risk patients with combined aortic and mitral regurgitation.

13 November 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
XLXintian Liu
Xintian Liu
HZHaojie Zhang
Haojie Zhang
WCWenlin Cheng
Wenlin Cheng
QFQingkun Fan
Qingkun Fan
ZLZhibing Lu
Zhibing Lu
GZGangcheng Zhang
Gangcheng Zhang
Background: Adverse effects of intravenous digoxin vary from patients and disease status, which should be closely monitored.Aims: To explore the safety profile of intravenous digoxin in acute heart failure with reduced ejection fraction (HFrEF) among Chinese patients.Methods: A clinical prospective, single-center, single-arm, open-label exploratory clinical trial was performed in patients with acute HFrEF at Wuhan Asia Heart Hospital. A fixed dose of 0.5 mg digoxin was used intravenously once per day for 3 days. The normalized dosage of digoxin (NDD), toxic serum digoxin concentration (SDC), and adverse reactions of intravenous digoxin were recorded.Results: A total of 40 patients were recruited in the study. The SDC increased from 1.03 ± 0.34 ng/mL to 1.95 ± 0.52 ng/mL during treatment. 50% (20/40) patients reached a toxic SDC of 2.0 ng/mL, and toxic effects were seen in 30% (12/40) patients. Estimated glomerular filtration rate (eGFR) < 60 mL/min [HR: 5.269; 95% CI: 1.905–14.575, p = 0.001], NDD ≥7 μg/kg [HR: 3.028; 95% CI: 1.119–8.194, p = 0.029], and ischemic cardiomyopathy [HR: 2.658; 95% CI: 1.025–6.894, p = 0.044] were independent risk factors for toxic SDC. Toxic SDC was effectively identified [area under the receiver operating characteristic (ROC) curve = 0.85, p < 0.001] using this model, and patients would have a higher risk of toxicity with more risk factors.Conclusion: Intravenous digoxin of 0.5 mg was safe and effective for initial dose but not suitable for maintenance treatment in Chinese patients with acute HFrEF. Patients who had lower eGFR, received higher NDD, and had ischemic cardiomyopathy should be closely monitored to avoid digoxin toxicity.

9 August 2023 in European Heart Journal
Verified
Journal Article
Closed access
XZXuan Zheng
Xuan Zheng
JCJinsong Cao
Jinsong Cao
GZGangcheng Zhang
Gangcheng Zhang